"name","uuid:ID","instanceType","description","label","id","rationale"
"Study Design 1","ea7a0a5e-e040-447f-95ea-e31218be9e8d","StudyDesign","The main design for the study","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
